

## Journal Information

|               |                                                 |
|---------------|-------------------------------------------------|
| Journal Title | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA            |
| Publisher     | CIG MEDIA GROUP, LP                             |
| ISSN          | 2152-2650                                       |
| E-ISSN        | 2152-2669                                       |
| Database      | Clarivate                                       |
| Domain        | Health Sciences, Life Sciences, Social Sciences |

## Classification History

| Year      | A+ | A | B | C |
|-----------|----|---|---|---|
| 2026      |    | ✓ | ✓ |   |
| 2025      |    | ✓ | ✓ |   |
| 2024      |    | ✓ | ✓ |   |
| 2023      |    | ✓ |   |   |
| 2021/2022 |    | ✓ |   |   |
| 2020      |    | ✓ |   |   |
| 2019      |    | ✓ |   |   |
| 2018      |    | ✓ |   |   |

**Classification:** The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

## Recent Articles

|                                                                                                                                                                                                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Matching-Adjusted Indirect Comparison of Gecacitinib Monotherapy versus Ruxolitinib Monotherapy and Pelabresib-Ruxolitinib Combination in JAK Inhibitor-Naive Myelofibrosis Patients</b><br>2026-10<br>Authors: Yi Zhang, Hu Zhou, Junling Zhuang et al.<br>DOI: 10.1016/j.cml.2026.10.012          |
| <b>Health-related quality of life with mosunetuzumab plus polatuzumab vedotin in R/R LBCL: Phase 3 SUNMO trial</b><br>2026-10<br>Authors: Won-Seog Kim, Huilai Zhang, Dai Maruyama et al.<br>DOI: 10.1016/j.cml.2026.10.009                                                                            |
| <b>Real-World Outcomes in First-Line Venetoclax-Based Therapy in Patients With AML Ineligible for Intensive Chemotherapy: A Single Center Study</b><br>2026-10 Vol. 26 Issue 10 Pages 661-669<br>Authors: Cheryl H. Chang, Allison O. Taylor, Nia M. Mitchell et al.<br>DOI: 10.1016/j.cml.2026.07.018 |
| <b>Revumenib in Pediatric Acute Leukemia: Clinical Activity and Differentiation Syndrome from the AUGMENT-101 Study</b><br>2026-10<br>Authors: Branko Cuglievan, Samanta Catueno, Aziz Farhat et al.<br>DOI: 10.1016/j.cml.2026.10.013                                                                 |

**In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma**

2026-10 Vol. 26 Issue 10 Pages 670-688.e2

Authors: Markus Maulhardt, Lina J. Kolloch, Gina Westhofen et al.

DOI: 10.1016/j.clml.2026.08.002

**SOHO State of the Art Updates and Next Questions| Individualizing Treatment Selection in Myelofibrosis**

2026-10 Vol. 26 Issue 10 Pages 640-648

Authors: Anthony M. Hunter, Prithviraj Bose

DOI: 10.1016/j.clml.2026.07.010

**Use and safety of peripherally inserted venous catheters vs central venous catheters for patients with lymphoma receiving frontline anthracycline-based chemotherapy**

2026-10

Authors: Yun Kyoung Tiger, Danny Luan, Patrick Glennan et al.

DOI: 10.1016/j.clml.2026.10.022

**Targeting the Menin-KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success**

2026-10 Vol. 26 Issue 10 Pages 649-660

Authors: Claudia Simio, Alessandra Vatteroni

DOI: 10.1016/j.clml.2026.07.019

**Right ventricular global longitudinal strain derived by cardiac magnetic resonance in cardiac light-chain amyloidosis: improved prognostic model fit beyond staging and greater discrimination than echocardiography — a retrospective cohort study**

2026-10

Authors: Vasilis Mikros, Niki Lama, Georgios Georgiopoulos et al.

DOI: 10.1016/j.clml.2026.10.015

**Ataxia and Balance Disorders Associated with GPRC5D-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Case Series with Practical Recommendations for Management**

2026-10

Authors: Ja Min Byun, Vania Hungria, Niels W.C.J. van de Donk et al.

DOI: 10.1016/j.clml.2026.10.019